Literature DB >> 16696044

Accumulation of p53 protein in inverted transitional cell papilloma of the urinary bladder.

K W Chan1, K Y Lam, G Srivastava.   

Abstract

Aims-To study the possible accumulation of p53 protein in inverted papilloma of the urinary bladder.Methods-Formalin fixed, paraffin wax embedded sections from 14 cases of inverted papilloma of the urinary bladder were studied retrospectively. Accumulation of p53 was detected by immunohistochemistry using a mouse monoclonal antibody directed against p53. p53 protein reactivity was scored as follows: 0 = 10%; 1 = 10% to <30%; 2 = 30% to <50%; and 3 = >50% of cells p53 positive.Results-The 14 sections were scored as follows: 3 in four cases; 2 in four cases; 1 in one case; and 0 in five cases. Overall, nine (64%) of the 14 cases were positive for p53 protein.Conclusions-The accumulation of p53 protein in inverted papilloma of the urinary bladder suggests that p53 may have has an important role in the neoplastic process of this tumour. However, the benign nature of inverted papillomas suggests that p53 protein accumulation is not related to tumour invasiveness and metastasis. p53 reactivity cannot be used as a marker of malignancy for urothelial neoplasia. Further studies are required to determine the role of p53 protein in the oncogenesis of urothelial neoplasms.

Entities:  

Year:  1996        PMID: 16696044      PMCID: PMC408017          DOI: 10.1136/mp.49.1.m43

Source DB:  PubMed          Journal:  Clin Mol Pathol        ISSN: 1355-2910


  15 in total

1.  Urothelial carcinoma occurring within an inverted papilloma of the ureter.

Authors:  R Grainger; P W Gikas; H B Grossman
Journal:  J Urol       Date:  1990-04       Impact factor: 7.450

2.  Abnormal expression of wild type p53 protein in normal cells of a cancer family patient.

Authors:  D M Barnes; A M Hanby; C E Gillett; S Mohammed; S Hodgson; L G Bobrow; I M Leigh; T Purkis; C MacGeoch; N K Spurr
Journal:  Lancet       Date:  1992-08-01       Impact factor: 79.321

3.  P53 accumulation in precursor lesions and early stages of bladder cancer.

Authors:  B J Schmitz-Dräger; C R van Roeyen; M O Grimm; C D Gerharz; K Decken; W A Schulz; H Bültel; D Makri; T Ebert; R Ackermann
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

4.  High levels of p53 protein in UV-irradiated normal human skin.

Authors:  P A Hall; P H McKee; H D Menage; R Dover; D P Lane
Journal:  Oncogene       Date:  1993-01       Impact factor: 9.867

5.  p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer.

Authors:  H Moch; G Sauter; D Moore; M J Mihatsch; F Gudat; F Waldman
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  A case of inverted papilloma of the ureter: is the DNA ploidy pattern associated with occurrence of transitional cell carcinoma of the bladder?

Authors:  K Kunimi; T Uchibayashi; M Egawa
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

7.  Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder.

Authors:  A S Sarkis; G Dalbagni; C Cordon-Cardo; J Melamed; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal:  J Urol       Date:  1994-08       Impact factor: 7.450

8.  Abnormalities in p53 and DNA content in transitional cell carcinoma of the bladder.

Authors:  K Mellon; S Wilkinson; J Vickers; M C Robinson; B K Shenton; D E Neal
Journal:  Br J Urol       Date:  1994-05

9.  p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas.

Authors:  C Tenaud; A Negoescu; F Labat-Moleur; Y Legros; T Soussi; E Brambilla
Journal:  Mod Pathol       Date:  1994-10       Impact factor: 7.842

10.  p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.

Authors:  D Esrig; C H Spruck; P W Nichols; B Chaiwun; K Steven; S Groshen; S C Chen; D G Skinner; P A Jones; R J Cote
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.